Equity Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 12-12-2024
- Paid Up Capital ₹ 0.50 M
as on 12-12-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -27.10%
(FY 2022)
- Profit -96.31%
(FY 2022)
- Ebitda -8.65%
(FY 2022)
- Net Worth -6.79%
(FY 2022)
- Total Assets -40.15%
(FY 2022)
About Equity Pharmaceuticals
The Corporate was formerly known as Equity Pharmaceutical Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Tahir Mir, Javeed Bhat, Zahoor Bhat, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232CH2012PLC033648
- Company No.
033648
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
19 Mar 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Equity Pharmaceuticals Limited offer?
Equity Pharmaceuticals Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin & Multivitamin Injections, Dietary Supplements, Weight Loss Supplement, Digestive System Drugs & Medicines, Pre & Probiotic Capsule, Chemical Reagents & Catalysts, Potassium Salts, Antacid Drugs.
Who are the key members and board of directors at Equity Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Tahir Mir  | Director | 19-Mar-2012 | Current |
| Javeed Bhat | Director | 19-Mar-2012 | Current |
| Zahoor Bhat | Director | 19-Mar-2012 | Current |
| Asif Zargar | Director | 19-Mar-2012 | Current |
Financial Performance of Equity Pharmaceuticals.
Equity Pharmaceuticals Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 27.1% decrease. The company also saw a substantial fall in profitability, with a 96.31% decrease in profit. The company's net worth dipped by a decrease of 6.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Equity Pharmaceuticals?
In 2022, Equity Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Equity Pharmaceuticals?
Equity Pharmaceuticals has a workforce of 13 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Equity Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Equity Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
